A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 for Injection in Subjects with Advanced Solid Tumors

Phase 1/2

Recruiting

• Conditions: Ovarian Neoplasms

• Registration Number: 2024-513860-25-00
• Lead Sponsor: Glaxosmithkline Research & Development Limited, Glaxosmithkline Research & Development Limited

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study First Posted: 2024-10-22
• Last Update Posted: 2025-03-07

Recruitment & Eligibility

• Status: Ongoing, recruiting
• Sex: Not specified
• Target Recruitment: 85

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: Not specified
• Study Design: Not specified

Trial Locations

Locations (21)

UZ Leuven; 🇧🇪 Leuven, Belgium

Centre Leon Berard; 🇫🇷 Lyon, France

Institut De Cancerologie De L Ouest; 🇫🇷 Saint-Herblain Cedex, France

Institut Gustave Roussy; 🇫🇷 Villejuif, France

Humanitas Mirasole S.p.A.; 🇮🇹 Rozzano, Italy

Fondazione Policlinico Universitario Agostino Gemelli IRCCS; 🇮🇹 Rome, Italy

IRCCS Istituto Nazionale Tumori Fondazione Pascale; 🇮🇹 Naples, Italy

Hospital Universitario Fundacion Jimenez Diaz; 🇪🇸 Madrid, Spain

Hospital Universitari Vall D Hebron; 🇪🇸 Barcelona, Spain

Hospital Universitario Ramon Y Cajal; 🇪🇸 Madrid, Spain

Scroll for more (11 remaining)

UZ Leuven

🇧🇪Leuven, Belgium

Toon Van Gorp

Site contact

003216345126

toon.vangorp@uzleuven.be